MoAb May Improve Detection of Colon And Rectal Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

BOSTON--A radiolabeled monoclonal antibody (MoAb) currently under investigation may improve detection of recurrent colorectal cancer, said Dr. Frederick Moffat, associate professor of surgery, University of Miami Medical School.

BOSTON--A radiolabeled monoclonal antibody (MoAb) currently underinvestigation may improve detection of recurrent colorectal cancer,said Dr. Frederick Moffat, associate professor of surgery, Universityof Miami Medical School.

Results of a multicenter study, reported by Dr. Moffat at the48th Annual Cancer Symposium of the Society of Surgical Oncology(SSO), suggest that use of the radiolabeled antibody may complementCT scans in the detection of early recurrence of disease. A clinicalbenefit of the MoAb was found in 42% of 210 patients studied.

The diagnostic agent, called CEA-Scan (formerly known as ImmuRAID-CEA),is produced by Immunomedics, Inc., Morris Plains, NJ, and is currentlyunder review for marketing approval in the United States and Europe.

Use of CEA-Scan in addition to CT studies may help doctors determinewhether the patient is a good candidate for surgery, and may alsodirect the surgeon to metastases missed with CT scan alone (seefigure), Dr. Moffat said. He believes that "CT scanis overrated for the detection of recurrent colorectal cancer,"and that antibody-aided visualization will improve the detectionof recurrent and metastatic disease.

CEA-Scan is a technetium-99m labeled antibody fragment that recognizescarcinoembryonic antigen (CEA), a tumor marker for colorectalcancer and some breast and lung cancers. Because CEA-Scan is anantibody fragment, it avoids many of the problems that plagueother antibody-assisted imaging techniques, such as toxicity andthe production of human antimouse antibodies (HAMA), he said.Also, serum CEA levels do not adversely affect imaging efficacy.

Since CEA-Scan is labeled with technetium-99, it is relativelyinexpensive and easy to use, he said. The radiolabel can be injectedinto the antibody vial just prior to administration, and the wholeprocedure can be done on an outpatient basis.

Immunomedics, Inc. is currently evaluating the use of CEA-Scanfor breast and lung cancers. In addition, the company has justreceived an NCI grant to determine the clinical efficacy of ahumanized lymphoma-targeting antibody for therapy, according toexecutive vice president Amy Factor.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content